Navigation Links
Oramed Patent Allowed in the US for Oral Administration of Proteins
Date:9/24/2015

JERUSALEM, September 24, 2015 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins" has been allowed by the United States Patent and Trademark Office.

Nadav Kidron, CEO of Oramed, stated, "This is an important milestone which paves our entrance into the US diabetes market which is the largest single diabetes market worldwide."

About ORMD-0801 Capsule for Type 2 Diabetes 

ORMD-0801 has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. Orally administered insulin should bring with it enhanced patient compliance. In addition, intestinally absorbed-oral insulin actually mimics insulin's natural location and gradients in the body by first passing through the liver before entering the bloodstream.

About Oramed Pharmaceuticals 

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD[TM]) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801).  Having completed multiple Phase IIa clinical trials, the company has started its Phase IIb on type 2 diabetes under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition the company is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visit http://www.oramed.com

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss that our US patent is an important milestone which paves our entrance into the US diabetes market, that ORMD-0801 has the potential to create a new paradigm in the treatment of diabetes, potentially slowing disease progression and delaying or even eliminating late-stage complications, that orally administered insulin should bring with it enhanced patient compliance or revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the SEC.

Company Contact
Oramed Pharmaceuticals
Ariella Vaystooch
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: ariella@oramed.com


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Completes Randomization of Over 50% of Patients in Phase IIb Oral Insulin Study
2. Oramed to Present at the Rodman & Renshaw Global Investment Conference
3. Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China
4. Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study
5. Oramed Granted Patent in Russia for Oral Administration of GLP-1
6. Oramed Announces Closing of $5.36 Million Registered Direct Offering
7. Oramed to Raise $5.36 Million in Registered Direct Offering
8. Oramed to Present at the American Diabetes Association 75th Scientific Sessions
9. Oramed to Present at Upcoming Conferences
10. Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter
11. Oramed to Present at the GTC Diabetes Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2019)... ... August 16, 2019 , ... SignatureCare Emergency Center has ... Houston, TX including Montrose, Heights, Memorial City, and Bellaire, TX. , The one-day ... Heights, is aimed at helping Houston families get their children caught up on ...
(Date:8/16/2019)... (PRWEB) , ... August 16, 2019 , ... ... Road in Gainesville GA, 30501, is a comprehensive family dental practice that serves ... within general dentistry, cosmetic dentistry , endodontics and restorative dental care. The ...
(Date:8/16/2019)... ... August 16, 2019 , ... OCT Clinical ... it has successfully completed enrollment of 690 patients for a phase III efficacy ... multicenter, randomized, double-blind, placebo-controlled, home use, parallel group clinical trial of MED2002, which ...
Breaking Medicine Technology:
(Date:8/21/2019)... ... August 21, 2019 , ... Alsana ... in Huntsville, Ala. in early 2020. Alsana will offer an eating disorder treatment ... Outpatient Program (IOP). The integrative program will provide a continuum of care as ...
(Date:8/21/2019)... ... August 21, 2019 , ... Future ... July 28. The Phase II expansion of Providence Point in Pittsburgh’s Scott Township ... as construction of the 70-unit apartment tower, Hamilton Tower. , The ...
(Date:8/19/2019)... ... 2019 , ... Professional Enrollment Concepts (PEC), a top benefits ... have ranked #3056 on the 2019 Inc. 5000 Fastest-Growing Private Companies list. The ... most successful companies within the American economy's most dynamic segment—its independent small and ...
(Date:8/17/2019)... ... August 17, 2019 , ... ... America’s Fastest-Growing Private Companies—the Inc. 5000 , For the 2nd Year In a ... Revenue Growth of 192% Percent , Inc. magazine today revealed that YellowTelescope LLC ...
(Date:8/16/2019)... ... August 16, 2019 , ... Tim Stouffer, ICS ... Mid-Atlantic and North East at the 2019 Safety Academy sponsored through Associated Builders ... existing construction safety concepts and define not only a safety program but focus ...
Breaking Medicine News(10 mins):